FDA approves first veterinary amlodipine drug for feline hypertension: full analysis

The FDA has approved Amodip for the control of systemic hypertension in cats, giving veterinarians the first FDA-approved amlodipine product specifically for veterinary use. The agency announced the decision on April 29, 2026, describing Amodip as chewable amlodipine besylate tablets and noting that it is the second FDA-approved product for the control of hypertension in cats. dvm360 identified the sponsor as Ceva Santé Animale. (fda.gov)

The approval formalizes a treatment approach that feline practitioners have used for years. Amlodipine has been widely prescribed off-label from human products because it’s been considered the leading antihypertensive option for cats, particularly when hypertension is linked to chronic kidney disease, hyperthyroidism, diabetes, or other comorbidities. ISFM guidance recommends amlodipine as first-line therapy, especially when target-organ damage is present, and emphasizes that early treatment can preserve vision and reduce ongoing injury to the kidneys, eyes, brain, and heart. (journals.sagepub.com)

FDA’s announcement focused on the clinical consequences of uncontrolled blood pressure and on the need for active monitoring after treatment starts. The agency said cats on therapy should have regular blood pressure checks, with bloodwork monitored early in treatment for potential kidney and liver value changes. European product information for Amodip, which has already been marketed abroad, adds practical cautions familiar to internists: confirm persistent hypertension with repeated measurements to reduce the risk of treating white coat hypertension, investigate underlying disease, and monitor potassium and chloride during treatment, especially in older cats with CKD. The tablets are flavored, scored, and designed to be split into equal parts, which may help with dose titration and administration. (fda.gov)

The evidence base behind the product is also stronger than a simple label expansion story. A placebo-controlled clinical trial of a chewable amlodipine formulation in client-owned cats found meaningful systolic blood pressure reductions, and dvm360 reported treated cats showed a mean systolic reduction of 28.2 mm Hg. Earlier literature and consensus guidance have described typical reductions in the 40 to 70 mm Hg range in many hypertensive cats, depending on severity and dosing, with once-daily treatment often effective. In cats presenting with ocular target-organ damage, guidance has stressed that amlodipine should be started quickly because retinal changes may improve, but prolonged detachment can leave permanent vision loss. (dvm360.com)

Industry reaction was limited in the immediate coverage reviewed, but the broader clinical context is clear: this is less a therapeutic surprise than a regulatory catch-up to standard practice. For years, veterinarians have relied on human amlodipine products or extemporaneous approaches because no FDA-approved veterinary amlodipine option existed in the U.S. That gap mattered not because clinicians lacked a drug that worked, but because they lacked a feline-labeled formulation built around dosing flexibility, palatability, and an FDA-reviewed safety and efficacy package. (pmc.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, the approval could improve both workflow and consistency of care. Hypertensive cats are often older, medically complex patients already juggling CKD monitoring, thyroid management, retinal exams, and repeat blood pressure visits. A chewable, scored, feline-specific product may reduce friction for pet parents, improve adherence, and make dose adjustments more straightforward. It also gives practices a labeled option to discuss when hypertension is newly diagnosed or when ocular signs, neurologic changes, or renal progression raise urgency. At the same time, the approval doesn’t change the fundamentals: accurate blood pressure measurement still matters, white coat effects still complicate diagnosis, and underlying disease still has to be addressed alongside antihypertensive therapy. (medicines.health.europa.eu)

What to watch: The next practical questions are commercial rather than scientific: when Ceva will begin broad U.S. distribution, what the product will cost relative to human generic amlodipine and compounded alternatives, and when the FDA posts the full FOI summary with the underlying approval data. Clinicians will also be watching whether the new label shifts prescribing patterns in general practice, especially for senior cats with CKD or hypertensive retinopathy, where earlier diagnosis and easier treatment could have the biggest clinical payoff. (fda.gov)